<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657917</url>
  </required_header>
  <id_info>
    <org_study_id>A-13225</org_study_id>
    <nct_id>NCT00657917</nct_id>
  </id_info>
  <brief_title>Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396</brief_title>
  <official_title>Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this protocol is to treat laboratory confirmed cutaneous
      leishmaniasis with WR 279,396 in military health care beneficiaries. In this study &quot;cutaneous
      leishmaniasis&quot; is defined as Old World Leishmaniasis if acquired in the Southwest Central
      Asia/Middle East.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 10 volunteers, who are military health care beneficiaries, with a diagnosis of Old
      World cutaneous leishmaniasis who have failed pentavalent antimony or are not eligible to be
      treated with pentavalent antimony, will be treated with WR 279,396 (topical
      paromomycin-gentamicin-AQIC) twice a day for 20 days. Primary endpoint will be the appearance
      of complete epithelialization of each skin lesion by Day 50+/-2 weeks, or estimated 50%-99%
      re-epithelialization by Day 50+/-2 weeks followed by complete epithelialization by Day
      100+/-2 weeks,with both categories without relapse by Day 180+/-30 days. Efficacy will be
      evaluated by clinical appearance assessed by study investigator and documented with
      photographs of the treated skin lesions. Toxicity will be evaluated by local adverse
      reactions and by laboratory signs of systemic toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No subjects were enrolled since the first subject completed the study 08Jun2007
  </why_stopped>
  <start_date type="Actual">December 20, 2006</start_date>
  <completion_date type="Actual">June 24, 2010</completion_date>
  <primary_completion_date type="Actual">June 8, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Appearance of Complete Epithelialization of Ulcerative Lesions Caused by Old World Cutaneous Leishmaniasis With no Relapse</measure>
    <time_frame>180 days</time_frame>
    <description>Appearance of complete (100%) epithelialization of a skin lesion at day 50+2 weeks, or the estimated 50%-99% re-epithelialization by day 50+2 weeks followed by complete eipithelialization by day 100+2 weeks, with both categories without relapse by day 180+30 days. Ulcer measured in millimeters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Relapses</measure>
    <time_frame>180 days</time_frame>
    <description>Evaluate the number of relapses occurring by day 180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability (SAE's and AE's)</measure>
    <time_frame>180 days</time_frame>
    <description>Evaluate safety and tolerability as measured by completion of a full prescribed treatment course, treatment interruptions, SAE's and AE's</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Paromomycin +Gentamicin topical cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WR279,396 topically twice a day for 20 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paromomycin +Gentamicin topical cream</intervention_name>
    <description>WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.</description>
    <arm_group_label>Paromomycin +Gentamicin topical cream</arm_group_label>
    <other_name>WR279,396</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Parasitologically confirmed, primarily ulcerative, Old World CL, in a patient who had
        either failed pentavalent antimony treatment, or who was ineligible for pentavalent
        antimony therapy.

          -  Military health care beneficiary 18 years of age or greater, unless active military in
             which case, 17 years is the minimum age

          -  Proven parasitological diagnosis by culture, PCR or microscopy in at least one skin
             lesion

          -  Lesions primarily ulcerative (i.e., not verrucous or nodular)

          -  Written informed consent to participate in protocol

          -  Negative pregnancy test within 72 hours of starting protocol

          -  Agrees to take precautions not to become pregnant or father a child for at least two
             months after completion of treatment with WR 279,396

          -  Cutaneous leishmaniasis acquired in Southwest Central Asia/Middle East*

          -  Inadequate response to treatment with pentavalent antimony or medical condition that
             precludes the use of pentavalent antimony

        Exclusion Criteria:

          -  Drug intolerance: history of known or suspected hypersensitivity or idiosyncratic
             reactions to aminoglycosides in the patient

          -  any leishmanial lesion on mucosal surface

          -  Presence of signs or symptoms of peripheral neuropathic myasthenia gravis,
             neuromuscular block

          -  Routinely taking nephrotoxic or ototoxic medications

          -  Disseminated disease defined as clinically significant subcutaneous nodules that are
             in the lymphatic drainage tract for the skin lesion with regional adenopathy &gt; 1 cm

          -  Abnormal Romberg test at baseline

          -  Clinically significant medical problems of the kidney or liver as determined by
             history and by the following laboratory studies:

               -  Kidney: Creatinine &gt; 2x the upper limit of normal

               -  Liver: ASTor ALT &gt;4x the upper limit fo normal

                    -  This includes &quot;L. major,&quot; &quot;L. tropica,&quot; and &quot;L. infantum&quot; with over 98% of
                       cases in U.S. military in 2002-2004 being &quot;L. major&quot;

                         -  An inadequate response to treatment with pentavalent antimony includes
                            patients who show no or little improvement during a 15-20 day treatment
                            course, those that initially epithelialize but later show signs of
                            breakdown/ ulceration or develop new lesions. In general, for those
                            with initial treatment response, would recommend waiting for
                            approximately two months after pentavalent antimony and if lesion is
                            not epithelialized at that time, consideration for further therapy is
                            advised.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>COL Naomi Aronson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniformed Services Univ of the Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <results_first_submitted>May 2, 2017</results_first_submitted>
  <results_first_submitted_qc>August 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2019</results_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leishmaniasis</keyword>
  <keyword>cutaneous</keyword>
  <keyword>Old World</keyword>
  <keyword>Leishmania major</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Paromomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted at Walter Reed Army Medical Center, Washington, DC. One subject was enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Paromomycin +Gentamicin Topical Cream</title>
          <description>WR279,396 topically twice a day for 20 days
Paromomycin +Gentamicin topical cream: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paromomycin +Gentamicin Topical Cream</title>
          <description>WR279,396 topically twice a day for 20 days
Paromomycin +Gentamicin topical cream: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Appearance of Complete Epithelialization of Ulcerative Lesions Caused by Old World Cutaneous Leishmaniasis With no Relapse</title>
        <description>Appearance of complete (100%) epithelialization of a skin lesion at day 50+2 weeks, or the estimated 50%-99% re-epithelialization by day 50+2 weeks followed by complete eipithelialization by day 100+2 weeks, with both categories without relapse by day 180+30 days. Ulcer measured in millimeters.</description>
        <time_frame>180 days</time_frame>
        <population>Ultimately, the planned statistical analysis could not be performed because only one patient was enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin +Gentamicin Topical Cream</title>
            <description>WR279,396 topically twice a day for 20 days
Paromomycin +Gentamicin topical cream: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>The Appearance of Complete Epithelialization of Ulcerative Lesions Caused by Old World Cutaneous Leishmaniasis With no Relapse</title>
          <description>Appearance of complete (100%) epithelialization of a skin lesion at day 50+2 weeks, or the estimated 50%-99% re-epithelialization by day 50+2 weeks followed by complete eipithelialization by day 100+2 weeks, with both categories without relapse by day 180+30 days. Ulcer measured in millimeters.</description>
          <population>Ultimately, the planned statistical analysis could not be performed because only one patient was enrolled in the study.</population>
          <units>Surface area in millimeters squared</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2,142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20+3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1,488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50+14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1,400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180+30 (photos only)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Relapses</title>
        <description>Evaluate the number of relapses occurring by day 180</description>
        <time_frame>180 days</time_frame>
        <population>Ultimately, the planned statistical analysis could not be performed because only one patient was enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin +Gentamicin Topical Cream</title>
            <description>WR279,396 topically twice a day for 20 days
Paromomycin +Gentamicin topical cream: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Relapses</title>
          <description>Evaluate the number of relapses occurring by day 180</description>
          <population>Ultimately, the planned statistical analysis could not be performed because only one patient was enrolled in the study.</population>
          <units>Number of relapses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability (SAE's and AE's)</title>
        <description>Evaluate safety and tolerability as measured by completion of a full prescribed treatment course, treatment interruptions, SAE's and AE's</description>
        <time_frame>180 days</time_frame>
        <population>Ultimately, the planned statistical analysis could not be performed because only one patient was enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin +Gentamicin Topical Cream</title>
            <description>WR279,396 topically twice a day for 20 days
Paromomycin +Gentamicin topical cream: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability (SAE's and AE's)</title>
          <description>Evaluate safety and tolerability as measured by completion of a full prescribed treatment course, treatment interruptions, SAE's and AE's</description>
          <population>Ultimately, the planned statistical analysis could not be performed because only one patient was enrolled in the study.</population>
          <units>Number of AE's</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs Considered Related to Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE's Not Considered Related to Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 Days</time_frame>
      <desc>Solicited and unsolicited AEs were collected throughout the 20-day treatment period. Follow-up contacts to assess efficacy and safety occurred on study days 50+14, 100+14, and 180+30.</desc>
      <group_list>
        <group group_id="E1">
          <title>Paromomycin +Gentamicin Topical Cream</title>
          <description>WR279,396 topically twice a day for 20 days
Paromomycin +Gentamicin topical cream: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy (right inguinal area)</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Persistent lymphedema, left lower extremity</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent tachycardia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Right gluteal pain</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Worsening pain at ulcer site</sub_title>
                <description>Possibly related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Incomplete healing of ulcer/lesion</sub_title>
                <description>Definitely related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vesicle formation at ulcer site</sub_title>
                <description>Definitely related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blister-like formation above border of ulcer/lesion</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Small cut on left shin</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated BP readings</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Decreased sodium level</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Elevated percentage of monocytes in blood</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Elevated percentage of WBC in urine</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Left foot edema</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Edema, left leg to mid thigh</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Left calf pain</sub_title>
                <description>Possibly related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation at site</sub_title>
                <description>Possibly related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Numbness (slight) above ulcer/lesion</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Blood-tinged secretions from nares</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right groin rash</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cracked skin surrounding ulcer area</sub_title>
                <description>Possibly related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Erosive areas around ulcer border</sub_title>
                <description>Definitely related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash above surrounding area of ulcer/lesion</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Increased drainage from wound</sub_title>
                <description>Possibly related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Insufficient hypertension control</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperemic left leg</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to only 1 patient enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>COL Naomi Aronson MC</name_or_title>
      <organization>Uniformed Services University of the Heralth Sciences</organization>
      <phone>301-295-3621</phone>
      <email>naronson@usuhs.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

